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Abstract 
Background: the aim of this study is to perform an external validation for the Candiolo nomogram, a predictive algo-
rithm of biochemical and clinical recurrences in prostate cancer patients treated by radical Radiotherapy, published in 
2016 on the journal “Radiation Oncology”.
Methods: 561 patients, treated by Radiotherapy with curative intent between 2003 and 2012, were classified accord-
ing to the five risk-classes of the Candiolo nomogram and the three risk-classes of the D’Amico classification for com-
parison. Patients were treated with a mean prostatic dose of 77.7 Gy and a combined treatment with Androgen-Dep-
rivation-Therapy in 76% of cases. The end-points of the study were biochemical-progression-free-survival (bPFS) and 
clinical-Progression-Free-Survival (cPFS). With a median follow-up of 50 months, 56 patients (10%) had a biochemical 
relapse, and 30 patients (5.4%) a clinical progression. The cases were divided according to D’Amico in low-risk 21%, 
intermediate 40%, high-risk 39%; according to Candiolo very-low-risk 24%, low 37%, intermediate 24%, high 10%, 
very-high-risk 5%. Statistically, the Kaplan-Meier survival curves were processed and compared using Log-Rank tests 
and Harrell-C concordance index.
Results: The 5-year bPFS for the Candiolo risk-classes range between 98 and 38%, and the 5-year cPFS between 98 
and 50% for very-low and very-high-risk, respectively. The Candiolo nomogram is highly significant for the stratifica-
tion of both bPFS and cPFS (P < 0.0001), as well as the D’Amico classification (P = 0.004 and P = 0.001, respectively). 
For the Candiolo nomogram, the C indexes for bPFS and cPFS are 75 and 80%, respectively, while for D’Amico clas-
sification they are 64 and 69%, respectively. The Candiolo nomogram can identify a greater number of patients with 
low and very-low-risk prostate cancer (61% versus 21% according to D’Amico) and it better picks out patients with 
high and very-high-risk of recurrence, equal to only 15% of the total cases but subject to 48% (27/56) of biochemical 
relapses and 63% (19/30) of clinical progressions.
Conclusions: the external validation of the Candiolo nomogram was overall successful with C indexes approximately 
10% higher than the D’Amico control classification for bPFS and cPFS. Therefore, its clinical use is justified in prostate 
cancer patients before radical Radiotherapy.
Trial registration Retrospectively registered.
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Background
Prostate cancer is the most common cancer in men 
and the second leading cause of cancer death in males 
[1]. The early prediction of prostate cancer recurrences 
has inspired several modeling approaches, from classi-
cal statistical algorithms [2] till to more complex artifi-
cial intelligence methods, among which nomograms are 
very practical and popular tools. A lot of nomograms 
have been developed to guide therapy and predict out-
comes after radical Radiotherapy: one of the most pop-
ular classifications are D’Amico’s risk classes, which 
divide patients by pre-treatment PSA, clinical stage and 
biopsy Gleason Score (bGS) in three categories: low risk 
(PSA < 10 ng/ml and cT1–cT2a and bGS ≤ 6), intermedi-
ate risk (PSA 10–20 ng/ml or cT2b or bGS 7) and high 
risk (PSA > 20 ng/mL or clinical stage ≥ cT2c or bGS ≥ 8) 
[3, 4].
A new classification tool, the Candiolo nomogram (co-
funded by the European Commission through the CHIC 
project, “Computational Horizons In Cancer: Developing 
Meta and Hyper-Multiscale Models and Repositories for 
In-Silico Oncology”, Grant Agreement 600841), was pub-
lished in 2016 on the journal Radiation Oncology [5]. It 
predicts the risk of biochemical recurrence from prostate 
cancer in patients undergoing radical radiotherapy by 
dividing patients into five risk classes by combining five 
pre-treatment parameters, i.e. age, PSA at diagnosis, clin-
ical-radiological staging, biopsy Gleason Score (bGS) and 
percentage of biopsy positive cores (%PC).
In particular, the five parameters were categorized as 
follows: age ≥ 70 years or age < 70 years; PSA < 7 ng/mL, 
7–15 ng/mL or > 15 ng/mL; clinical-radiological stage 
cT1, cT2 or cT3-cT4; bGS ≤ 6, 3 + 4, 4 + 3, 8 or 9–10; 
%PC 1–20%, 21–50%, 51–80% or 81–100%. Then, the 
patients were split into five risk classes (very-low, low, 
intermediate, high, and very-high) according to the Can-
diolo nomogram scores shown in Fig. 1 and Table 1.
The nomogram training cohort consisted of 2493 men 
belonging to the EUREKA-2 multicenter retrospective 
database on prostate cancer; they were treated with exter-
nal-beam radiotherapy (EBRT) as primary treatment in 
north-western Italy between 1997 and 2012. The repro-
ducibility of the multivariate analysis Cox regression 
model was verified with a bootstrap statistic as internal 
validation. The Candiolo nomogram was highly signifi-
cant for the prediction of biochemical Progression Free 
Survival (bPFS) overall (log-rank test with P < 0.0001) and 
for the distinction of paired curves (all log-rank tests for 
paired curves with P < 0.001). The nomogram was then 
applied to the secondary end-points clinical Progression 
Fig. 1 The Candiolo nomogram
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Free Survival (cPFS), systemic Progression Free Survival 
and Prostate Cancer Specific Survival (overall log-rank 
tests always with P < 0.0001).
Thereafter, the Candiolo nomogram was compared 
with the classification of D’Amico made up of three risk 
classes. The Candiolo nomogram in the training cohort 
exceeded the D’Amico classification for all the outcomes 
considered with Harrell’s C Concordance Indexes of 
71.5% versus 63% for bPFS and 75.5% versus 65.5% for 
cPFS. For the five risk classes of the Candiolo nomogram 
the five-year bPFS were 94%, 85%, 80%, 67 and 43%, while 
for the three D’Amico risk classes they were much more 
compressed at 91%, 83 and 72%. Similarly, the cPFS for 
the Candiolo nomogram were 97%, 94%, 92%, 79 and 
62%, while for the D’Amico classes they were 96%, 91 and 
85%.
The main limitation of the Candiolo nomogram study 
is the lack of an external validation. This study aims to 
verify the reliability of the Candiolo nomogram on an 
independent database of patients treated by EBRT, always 
using the D’Amico classification as a control.
Methods
 The Department of Radiation Oncology of “Città della 
Salute e della Scienza” hospital, University of Torino, 
provided the validation cohort.  The validation study 
proposed by Prof. U. Ricardi was approved by the hos-
pital Ethics Committee on the 25th September 2015 as a 
retrospective historical cohort study on prostate cancer 
patients treated by radical EBRT.
The validation database was recorded in Excel format 
(®Microsoft Corporation, Redmond, Washington, USA) 
and included diagnostic data, comprising the data neces-
sary for the attribution of the risk class of the Candiolo 
nomogram (age, pre-treatment PSA, clinical-radiological 
staging, bGS, number of total and positive biopsy cores), 
therapeutic data on the performed Radiotherapy and 
Androgen Deprivation Therapy (ADT), and biochemical 
and clinical follow-up of the patients.
The inclusion criteria of the study were: histologi-
cal diagnosis of prostate adenocarcinoma; radical 
Radiotherapy as a first-line treatment, performed with 
conformational or intensity-modulated technique; tem-
poral consecutiveness of the clinical cases collected. Two 
Radiation Oncologists, A. Guarneri and S. Bartoncini, 
collected the clinical data of 930 patients treated con-
secutively in their Department between 1st January 2003 
and 31st December 2012.
In all patients, staging included medical history, physi-
cal examination with Digital Rectal Examination (DRE), 
serum PSA, and Trans-Rectal Ultrasound-guided biopsy 
of the prostate (TRUS) with histological evaluation of 
the biopsy Gleason Score (bGS). Radiological exams 
(abdominal CT, endo-rectal or pelvic MRI and bone 
scan) were performed according to the patient’s risk class 
and the opinion of the referring physician. Pre-treatment 
PSA was dosed prior to biopsy and radiological studies; 
in case of multiple pretreatment PSA exams, the high-
est PSA (zenith PSA) was recorded. Primary, secondary, 
and total bGS were attributed according to the 2005 ISUP 
Gleason Score review system [6]. The clinical-radiological 
stage of the primary tumor cT was obtained according to 
the 2011 AJCC 7th edition staging system [7] by integrat-
ing the clinical examination with all available radiological 
information, while data on the extent of cancer at biopsy 
were not taken into consideration.
All the patients were treated with Conformational 
Radiotherapy (3DCRT) or Intensity Modulated and 
Image-Guided Radiotherapy (IMRT-IGRT) with a cura-
tive intent. Fractionation schedules for the prostate CTV 
(Clinical Target Volume of the prostate) varied between 
standard fractionation of 2  Gy per fraction and moder-
ate hypo-fractionation of 2.7 Gy per fraction. The treat-
ment scheme consisted of either exclusive Radiotherapy 
or combined Radiotherapy and Androgen Deprivation 
Therapy (ADT). The androgen deprivation drugs used 
were anti-androgens or LHRH-analogues or TAB (Total 
Androgenic Block, i.e. the combination of the two previ-
ous drugs).
Standard follow-up included PSA and DRE every 3 
months for the first 2 years, every 6 months until the fifth 
year, and annually thereafter.
The end-points considered were the biochemical Pro-
gression Free Survival (bPFS) and the clinical Progres-
sion Free Survival (cPFS). Biochemical recurrence was 
assessed according to the definition of the Phoenix con-
sensus conference [i.e. an increase of 2 ng/mL or greater 
compared to post-irradiation nadir PSA [8]]. Clinical 
relapse was defined as a recurrence in the irradiated 
Table 1 Candiolo nomogram’s scores
bGS  ≤ 6 3 + 4 4 + 3 8 9–10
Points 0 35 48 76 106
cT cT1 cT2 cT3-4
Points 0 17 58
PSA  < 7 7–15  > 15
Points 0 42 96
%PC 1–20% 21–50% 51–80% 81–100%
Points 0 29 50 81
Age  ≥ 70 yy  < 70 yy
Points 0 22
Risk-class Very-low Low Intermediate High Very-high
Total points 0–56 57–116 117–193 194–262 263–363
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prostate gland, or in the regional pelvic lymph nodes or 
as distant metastases demonstrated by radiological exams 
(bone scan, choline-PET-CT, MRI, CT, ultrasound), or by 
a clinical examination, or by biopsy.
Regarding the privacy of patients’ personal data, a 
pseudo-anonymization procedure was performed, i.e. 
only the clinical data, and not the personal data, were 
sent outside the hospital in the database for data analyses.
Statistical analyses were performed by D. Gabriele and 
M. Tamponi using the statistical software Stata SE 14.0 
(®StataCorp, Texas, USA).
The data were filtered to be complete for all the diag-
nostic parameters mandatory for the application of the 
Candiolo nomogram. This procedure led to a loss of 369 
patients (354 without the number of positive and total 
biopsy cores, 10 without bGS, 3 without PSA, 2 without 
staging) leading to a reduction of the validation cohort 
from 930 to 561 patients.
The %PC was calculated by multiplying 100 by the 
number of prostate cancer positive cores, of any length, 
and then dividing by the total number of cores sampled. 
Age at treatment was calculated as the difference in years 
between the first day of radiotherapy and the date of 
birth. The follow-up time was calculated as the difference 
in months between the date of the patient’s last follow-up 
and the last day of radiotherapy, rounded to the nearest 
whole number. The categorical variables were coded in 
numerical format, both as ordinal variables (for example 
0,1,2,3, etc.) and as dummy variables with reference cell 
coding system (0, 1).
All radiotherapy doses were normalized to an Equiva-
lent Dose at 2 Gy per fraction (ED2Gy) using a mean α/β 
ratio of 2.5 Gy for prostate cancer (according to the liter-
ature the α/β for prostate cancer varies between 1.5 and 
5.7 Gy [9–11]).
Table 2 presents the main clinical-epidemiological data 
of the 561 patients under analysis. The median follow-up 
was 50 months. During the follow-up 56 patients (10% of 
the total) had a biochemical recurrence and 30 (5.4%) had 
a clinical-radiological progression (10 cases relapsed in 
the prostate, 9 in the pelvic lymph nodes and 18 had bone 
metastases).
Mean age was 71.9 years, mean PSA 12.93 ng/mL, 63% 
of patients were staged cT1, 32% cT2 and only 4% cT3 or 
cT4, 43% had a bGS of 7, followed by 39% with bGS ≤ 6 
and 18% with a bGS ≥ 8. The number of biopsy cores 
sampled was on average 11, with a mean percentage of 
biopsy positive cores of 41.3%. Only 4 patients (0.7%) 
were classified as cN1 at staging.
According to the D’Amico classification, patients were 
at low, intermediate, and high risk in 21%, 40 and 39% 
of cases, respectively. According to the Candiolo nomo-
gram, patients were at very-low, low, intermediate, high, 




Mean (SD) 56.5 (27.7)
Median (min–max) 50 (3–146)
Age, yy
Mean (SD) 71.9 (5.7)
Median (min–max) 73 (51–88)
PSA, ng/mL
Mean (SD) 12.93 (30.96)
Median (min–max) 7.70 (1.14–680)





 ≤ 6 220 (39%)
3 + 4 174 (31%)
4 + 3 69 (12%)
8 55 (10%)
9–10 43 (8%)
Biopsy cores sampled, no
Mean (SD) 11.0 (4.6)
Median (min–max) 10 (2–35)
%PC, %
Mean (SD) 41.3% (27.8)


















RT dose to prostate-CTV, ED2Gy, α/β = 2,5
Mean (SD) 77.7 (2.4)
Median (min–max) 78 (72–82)
Fractionation schedule, %
Std fractionation 2 Gy /fr 77%
Hypo-fractionation 2,7 Gy /fr 23%
RT technique, %
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and very-high risk in 24%, 37%, 24%, 10 and 5% of cases, 
respectively.
The mean RT dose to the prostate CTV was 77.7  Gy. 
The fractionation schedule was standard at 2 Gy/fraction 
with 3DCRT technique in 77% of cases and moderately 
hypo-fractionated at 2.7  Gy/fraction with IMRT-IGRT 
technique in 23% of cases. Seminal vesicles were irradi-
ated in 78% of patients, while pelvic lymph nodes only 
in 2% of cases. Treatment consisted of exclusive Radio-
therapy or Radiotherapy combined with ADT in 24 and 
76% of cases, respectively. When administered, the ADT 
had a median duration of 8 months (and a mean of 13 
months) and the drugs used were anti-androgens in 37% 
of patients, LHRH-analogues in 49% or TAB in 14% of 
cases.
The 561 patients were then assigned to the risk classes 
of the Candiolo nomogram according to the scores 
described in Table 1, and the patients were also catego-
rized into the three risk classes of the D’Amico classifica-
tion for comparison.
The Kaplan-Meier survival curves for bPFS and cPFS 
were graphed for the two classifications of Candiolo and 
D’Amico. The statistical significance for the whole set of 
curves and for couples of curves were calculated using 
Log-Rank tests.
The Harrell C concordance index was also calculated 
to evaluate the overall accuracy and predictive ability of 
the classifications. The concordance index was calculated 
according to the formula C = (E + T/2) /P, where P are 
the survival comparison Pairs combined among the N 
subjects analyzed, E are the number of pairs ordered as 
Expected and T the number of non-informative predic-
tions (Tied pairs).
Results
Kaplan–Meier survival curves for bPFS and cPFS for the 
five risk classes of the Candiolo nomogram and for the 
three risk classes of D’Amico classification are shown in 
Fig. 2.
For the Candiolo nomogram, the 5-year bPFS range 
between 98%, 93%, 90%, 80 and 38% for very-low, low, 
intermediate, high, and very-high risk, respectively, as 
well as 5-year cPFS vary between 98%, 98%, 94%, 89 and 
50%, respectively. For the three classes of D’Amico clas-
sification, the 5-year bPFS vary between 95%, 92 and 
83% for low, intermediate, and high risk, respectively, 
while the 5-year cPFS range between 99%, 97 and 88%, 
respectively.
Regarding the log-rank tests performed on the bPFS 
and cPFS curves, for the Candiolo nomogram the overall 
tests are highly significant for both endpoints (P < 0.0001) 
and the tests for paired curves are all significant (P < 0.05) 
except the difference between low and intermediate risk 
for bPFS (P = 0.37) and between very-low and low risk 
for cPFS (P = 0.47). For D’Amico classification the overall 
Log-Rank tests are highly significant for both bPFS and 
cPFS (P = 0.004 and P = 0.001, respectively), and the tests 
for paired curves are all significant (P < 0.05) except the 
difference between low and intermediate risk for cPFS 
(P = 0.52).
Analyzing the concordance indexes, for the Candi-
olo nomogram the C indexes are 75 and 80% for bPFS 
and cPFS, respectively, while for the classification of 
D’Amico they are equal to 64 and 69% for bPFS and cPFS, 
respectively.
Discussion
The external validation of the Candiolo nomogram on 
our series of 561 patients affected by prostate cancer and 
treated with radical Radiotherapy was overall successful. 
In fact, Harrell’s C concordance indexes are about 10% 
higher than the D’Amico control classification for bPFS 
(75% versus 64%) and cPFS (80% versus 69%).
In particular, the Candiolo nomogram can better iden-
tify patients with a high and very-high risk of relapse 
equal to only 15% of the total cases but subject to 48% 
(27/56) of biochemical relapses and 63% (19/30) of clini-
cal progressions.
Furthermore, the Candiolo nomogram can identify a 
greater number of low-risk patients than the classifica-
tion of D’Amico. In fact, according to the D’Amico clas-





Seminal vesicles irradiation, %
No 22%
Yes 78%




RT + ADT 76%
ADT duration, mo
Mean (SD) 13.0 (10.1)





SD, standard deviation; ED2Gy, equivalent dose at standard dose of 2 Gy per 
fraction; RT, radiotherapy; ADT, androgen deprivation therapy
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a bPFS of 95% and a cPFS of 99%; according to Candiolo, 
the sum of very-low and low risk patients is equal to 61% 
of total cases with an average bPFS of 95% and an average 
cPFS of 98%, substantially equivalent to the survivals of 
D’Amico low risk class.
However, while the distinction of the two high and 
very-high risk groups from the remaining risk classes is 
clear, it can be noted that the low risk curve sticks alter-
natively to the intermediate risk in bPFS and the very-low 
risk in cPFS.
To identify the factors that may have reduced the sta-
tistical significance in the external validation study, a 
comparison between the cases used in the training and 
validation cohorts, illustrated in Table 3, may be useful.
First, an important factor for the statistical power of 
the study is the difference in the sample size, respectively 
of 2493 and 561 patients for the training and validation 
cohorts, respectively.
In addition, a slight difference can be noted between 
the two cohorts with a greater percentage of very-low or 
low risk cases according to Candiolo nomogram in the 
validation cohort compared to the training one (61% ver-
sus 52%, respectively) and a lower percentage of high and 
very-high risk cases (15% versus 20%, respectively).
Besides, the validation series was treated with slightly 
higher and more homogeneous radiotherapy doses than 
the training one (mean dose of 77.7 versus 75.5 Gy and 
SD of 2.4 versus 3.0 Gy, respectively).
Regarding therapy, a second important factor of dis-
crepancy between the two series appears: in fact, the 
validation patients were treated in a greater percent-
age with a schedule combining Radiotherapy and ADT 
(76% versus 62% in the training series). Furthermore, 
in the validation series, ADT, when administered, was 
heavy both in terms of duration (13 months on average) 
and of the pharmacological class used (LHRH-analogue 
or TAB in 63% of cases). The intensive use of ADT can 
account for the flattening upwards of the low and inter-
mediate risk curves of the Candiolo nomogram and 
of the D’Amico classification in both bPFS and cPFS 
graphs. So, ADT may cause a shoulder in the survival 
curves, early in the follow-up for bPFS (combined 
Fig. 2 Validation cohort bPFS (a, b) and cPFS (c, d) for Candiolo nomogram (a–c) and D’Amico classification (b–d)
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radiotherapy and ADT in the first 12 months of follow-
up) or later in the follow-up for cPFS (rescue ADT after 
biochemical relapse).
The combined effect of a lower statistical power and 
the ADT shoulder could explain the deficit of statisti-
cal significance in the distinction between low and 
intermediate risks in the Candiolo nomogram (non-
statistically significant differences between low and 
intermediate risk for bPFS and between very-low and 
low risk for cPFS) as well as in the D’Amico control 
classification (non-statistically significant difference 
between low and intermediate risk for cPFS).
Another question to be explored is also how much 
the D’Amico classification published the first time 
in 1999 [3] can currently be considered the golden 
standard classification with which to compare; in fact, 
even if the classification of D’Amico is still widely used 
by Radiation Oncologists and Urologists for its simplic-
ity and robustness, the newest classification system is 
the NCCN classification of 2018 [12–15]. The NCCN 
classification combines PSA at diagnosis, TNM clini-
cal staging, bGS, number of positive cores at biopsy, 
percentage of cancer inside each core, and PSA density 
into a classification of six risk classes, i.e. very-low, low, 
intermediate favorable, intermediate unfavorable, high, 
and very-high risk (excluding regional class N1 and 
metastatic class M1).
Comparing the Candiolo nomogram to the NCCN 
classification, we can see several affinities: the subdivision 
of the Gleason Score into 5 risk classes (≤ 6, 3 + 4, 4 + 3, 8 
and 9–10); the attempt to integrate the information con-
cerning the extension of the tumor at biopsy (percentage 
or number of positive cores) within the risk groups; and 
a greater number of risk groups than the traditional three 
classes of D’Amico.
Among the advantages of the Candiolo nomogram are 
the following: it takes into account a smaller number of 
total factors than the NCCN classification; overall it is a 
simpler classification and it can be applied quickly using 
the nomogram scores; uses the prognostic factor age 
(easily available); in the very-low risk, it does not require 
data on the percentage of cancer within each core or on 
the prostate volume for the calculation of the PSA den-
sity (needing a detailed histological examination and an 
ultrasound exam of the prostate with an estimation of the 
prostate volume); besides, it classifies in the very-low risk 
class a wider number of patients, including some with a 
bGS of 3 + 4 and even a few with 4 + 3, that may be eligi-
ble for active surveillance [16].
Among the advantages of the NCCN classification are 
the following: it provides for a greater division into 6 risk 
groups compared to the 5 of the Candiolo nomogram, in 
particular by dividing the intermediate risk into inter-
mediate favorable and intermediate unfavorable, useful 
for the definition of patients suffering from intermedi-
ate risk in which a prophylactic pelvic irradiation of the 
lymph node drainage stations may be recommended; fur-
thermore, it considers PSA density as an additional factor 
for the classification of very-low risk tumors, worthy of 
watchful waiting.
It should also be noted that, given the importance of 
the extension of cancer at biopsy as a prognostic factor in 
both the Candiolo and NCCN classifications, a potential 
danger of reduced applicability of the two classifications 
could arise in the future linked to the modality of the 
biopsy procedure. In fact, nowadays most prostate can-
cers are biopsied under ultrasound guidance by sampling 
the whole prostate (10–12 cores, sampled in the right and 
Table 3 Comparison between the training cohort and the 
validation cohort of the Candiolo nomogram
Clinical characteristics Training cohort Validation cohort
Sample size 2,493 561
Median Follow-up, mo 50 50
Mean age, yy 71.7 71.9






 ≤ 6 48% 39%
3 + 4 22% 31%
4 + 3 11.5% 12%
8 12% 10%
9–10 6.5% 8%
Biopsy cores sampled, mean no 10.3 11.0
%PC, mean % 44.3% 41.3%











Mean (SD) 75.5 (3.0) 77.7 (2.4)
Median (min–max) 76.0 (67.1–81.1) 78.0 (72–82)
Exclusive RT, % 38% 24%
RT + ADT, % 62% 76%
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left apex, middle gland, and base): the result is therefore 
a reliable estimate of the extent of cancer with respect to 
the total prostate volume. A few cancers are already biop-
sied by targeting the suspect nodule visualized by multi-
parametric MRI under the guidance of the same MRI 
or by ultrasound guidance with image fusion between 
multi-parametric MRI and ultrasound [17, 18]: the cores 
sampled with these targeted procedures are often positive 
and therefore overestimate, sometimes widely, the extent 
of the cancer compared to the whole prostate. If MRI-
guided targeted biopsy techniques will spread widely, the 
data on the extension of cancer at biopsy would there-
fore be overestimated, or even worthless for prognostic 
purposes, limiting the accuracy or even the applicability 
of both classifications. A possible solution would be to 
use data strictly associated with the number of positive 
cores, but less or not affected at all by a targeted biopsy, 
such as the percentage of tumor inside each core (even 
in the presence of positive targeted cores a small nodule 
will still contain healthy tissue entering and exiting the 
nodule within the core) [19] or a radiological volumetric 
estimate of the extent of the cancer (for example by MRI). 
However, this approach would require ancillary studies 
to confirm a high correlation between the percentage or 
number of positive cores and the percentage of tumor 
inside each core or, even better, the radiological volume 
of prostate cancer, so that these parameters can reliably 
substitute the data on positive cores.
It should also be considered that patients in our study 
were staged mostly with CT, MRI and bone scan, while 
choline-CT-PET was not used, nor the more modern 
PSMA tracer. This might have lowered the ability to 
detect nodal and bone metastases at diagnosis in the high 
risk population.
Finally, it must always be taken into consideration that 
the choice of a different pre-treatment classification sys-
tem (D’Amico, Candiolo, NCCN) can have important 
consequences on the therapeutic choices, such as dose 
escalation on prostate cancer [20], irradiation of the sem-
inal vesicles [21, 22], prophylactic pelvic nodal irradiation 
[23], use of a combined treatment including Radiother-
apy and short-term or long-term ADT [24, 25].
Conclusions
The external validation of the Candiolo nomogram on 
a series of 561 patients affected by prostate cancer and 
treated with radical Radiotherapy was overall success-
ful. In fact, Harrell’s C concordance indexes are about 
10% higher than the D’Amico control classification for 
biochemical Progression Free Survival (75% versus 64%, 
respectively) and for clinical Progression Free Survival 
(80% versus 69%, respectively).
In particular, the Candiolo nomogram can identify a 
greater number of patients with low and very-low risk 
prostate cancer (61% versus 21% according to D’Amico 
classification) and it better picks out patients with high 
and very-high risk of relapse, equal to only 15% of the total 
cases but subject to 48% (27/56) of biochemical relapses 
and 63% (19/30) of clinical progressions.
Besides, we recommend the development of a nomo-
gram integrating pre-treatment diagnostic risk factors with 
therapeutic information (like RT dose, ADT and rectal-
bladder preparation protocol for radiotherapy set-up) [26, 
27] and we also advise the development of follow-up pro-
grams customized to the patient’s risk of relapse.
Therefore, the Candiolo nomogram has overcome the 
external validation with respect to the traditional clas-
sification of D’Amico and its clinical use is justified in 
prostate cancer patients for risk class assessment before 
radical Radiotherapy.
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